# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | ISEC Healthcare Ltd. |
| Establishment Date | October 28, 2014 |
| Headquarters Location | Singapore, Singapore |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | The Company invests in software development, with capitalised software under development amounting to $234,000 as of 31 December 2024, and maintains computer software amortised over an estimated useful life of 5 years. It operates a Performance Share Plan (2025 PSP) to incentivize key personnel, replacing the 2016 PSP, which supports talent retention and performance alignment. The Group has established a Risk Governance and Internal Control Framework Manual, including policies such as Code of Ethics and Risk Appetite Guidance, overseen by a Chief Risk Officer, to maintain robust risk management and internal controls. | The Group conducts specialist training courses for trainee ophthalmologists and medical staff, including the ISEC Intermediate Cataract Surgery course, focusing on advanced eye healthcare treatments and procedures. It maintains a risk governance and internal controls framework manual and has appointed a Chief Risk Officer to oversee risk management systems. The Group also capitalises on acquired computer software and software under development, amortised over an estimated useful life of five years. |
| Product Advantages | The Group provides clinical and medical eye care services across multiple countries including Singapore, Malaysia, and Myanmar, with revenue primarily derived from walk-in patients and a diverse customer base. It offers specialized eye screenings and treatments, including myopia control management with Hoya MiYOSMART and dry eye treatment, supported by ongoing staff training programs. The Company hosts educational events such as the ISEC Glaucoma Symposium and provides clinical attachments to over 200 students annually, enhancing service quality and expertise. | The Group offers a portfolio of ophthalmology services across multiple countries including Singapore, Malaysia, and Myanmar, serving mainly walk-in patients. It provides clinical and medical services with a focus on eye healthcare, including treatments for age-related macular degeneration and use of Optical Coherence Tomography Angiography (OCTA) imaging technology. |
| Brand Recognition | ISEC Healthcare Ltd. maintains long-term relationships with shareholders and stakeholders through transparent corporate governance and active engagement, including physical annual general meetings and detailed disclosures via SGXNet and its website. The Company is recognized for its commitment to community health through regular free eye screenings and collaborations with academic institutions. It is part of the Aier Eye Hospital Group network, which is listed on the Shenzhen Stock Exchange, linking it to a broader recognized healthcare group. | The Group is committed to maintaining long-term relationships with shareholders and stakeholders through transparent corporate governance and regular communication. It is recognized for its commitment to high standards of corporate governance and has a Performance Share Plan to engage employees in company growth. The Group also participates actively in community and educational activities to enhance its reputation. |
| Reputation Ratings | The Company adheres to the Code of Corporate Governance 2018 and related practice guidance pursuant to SGX Catalist Rules, with regular Board briefings on regulatory updates and sustainability reporting. It publishes an annual sustainability report addressing environmental, social, and governance (ESG) factors, including corporate governance and workforce development. The Group's internal controls and risk management systems are reviewed annually and deemed adequate and effective by the Audit Committee and Board for FY2024. | The Group publishes a sustainability report detailing its environmental, social, and governance (ESG) strategy, including corporate governance and workforce development. It adheres to the Code of Corporate Governance 2018 and related practice guidance pursuant to SGX Catalist Rules. The Audit Committee reviews the adequacy and effectiveness of internal controls and risk management annually, with assurance provided by the CEO and CFO on the adequacy of these systems for FY2023. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | N/A |
| Vision Statement | Our hope and vision is for treatment to be accessible and convenient for all. |
| Core Values | N/A |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 74,197.0 | 69,994.0 | 62,954.0 | Thousands | USD |
| Cost of Goods Sold | (41,529.0) | (38,958.0) | N/A | Thousands | USD |
| Gross Profit | 32,668.0 | 31,036.0 | 28,800.0 | Thousands | USD |
| Operating Expense | (15,908.0) | (13,942.0) | N/A | Thousands | USD |
| Operating Income | N/A | N/A | N/A | Thousands | USD |
| Net Profit | 12,894.0 | 13,150.0 | 12,700.0 | Thousands | USD |
| Income before income taxes | 17,187.0 | 17,314.0 | 16,778.0 | Thousands | USD |
| Income tax expense(benefit) | (4,293.0) | (4,164.0) | (4,050.0) | Thousands | USD |
| Interest Expense | (602.0) | (651.0) | (555.0) | Thousands | USD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 119,046.0 | 107,107.0 | 110,295.0 | Thousands | USD |
| Current Assets | 24,855.0 | 27,021.0 | 27,617.0 | Thousands | USD |
| Non-Current Assets | 94,191.0 | 80,086.0 | 82,678.0 | Thousands | USD |
| Total Liabilities | 27,307.0 | 24,957.0 | 28,953.0 | Thousands | USD |
| Current Liabilities | 16,766.0 | 14,469.0 | 16,096.0 | Thousands | USD |
| Non-Current Liabilities | 10,541.0 | 10,488.0 | 12,857.0 | Thousands | USD |
| Shareholders' Equity | 91,739.0 | 82,150.0 | 81,342.0 | Thousands | USD |
| Retained Earnings | 23,685.0 | 17,476.0 | 15,054.0 | Thousands | USD |
| Total Equity and Liabilities | 119,046.0 | 107,107.0 | 110,295.0 | Thousands | USD |
| Inventories | 2,501.0 | 2,235.0 | 1,874.0 | Thousands | USD |
| Prepaid Expenses | 436.0 | 334.0 | 293.0 | Thousands | USD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 17,642.0 | 17,171.0 | 17,848.0 | Thousands | USD |
| Net Cash Flow from Investing | (12,780.0) | (6,432.0) | (11,600.0) | Thousands | USD |
| Net Cash Flow from Financing | (9,129.0) | (11,305.0) | (7,167.0) | Thousands | USD |
| Net Increase/Decrease in Cash | (4,267.0) | (566.0) | (919.0) | Thousands | USD |
| Dividends | (6,615.0) | (10,541.0) | (4,398.0) | Thousands | USD |


## S2.4: Key Financial Metrics

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Gross Margin | 155.97% | 155.66% | N/A | Thousands | USD |
| Operating Margin | N/A | N/A | N/A | Thousands | USD |
| Net Profit Margin | 17.38% | 18.79% | 20.17% | Thousands | USD |
| Current Ratio | 148.25% | 186.75% | 171.58% | Thousands | USD |
| Quick Ratio | 130.73% | 169.00% | 158.11% | Thousands | USD |
| Interest Coverage | N/A | N/A | N/A | Thousands | USD |
| Asset Turnover | 65.62% | 64.39% | N/A | Thousands | USD |
| Debt-to-Equity | 29.77% | 30.38% | 35.59% | Thousands | USD |
| Return on Equity | 14.83% | 16.09% | N/A | Thousands | USD |
| Return on Assets | 11.40% | 12.10% | N/A | Thousands | USD |
| Effective Tax Rate | 24.98% | 24.05% | 24.14% | Thousands | USD |
| Dividend Payout Ratio | 51.30% | 80.16% | 34.63% | Thousands | USD |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Specialised health services: 70,601, General health services: 3,596 | Specialised health services: 66,015, General health services: 3,979 | Specialised health services: 58,514, General health services: 4,440 |
| Revenue by Geographic Region | Singapore: 11,852, Malaysia: 59,597, Myanmar: 2,748 | Singapore: 12,047, Malaysia: 55,960, Myanmar: 1,987 | Singapore: 11,342, Malaysia: 49,696, Myanmar: 1,916 |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | Revenue has shown a consistent growth trend from 2022 to 2024, increasing from 62,954 in 2022 to 69,994 in 2023, and further to 74,197 in 2024, representing a growth of approximately 11.5% from 2022 to 2023 and 6.3% from 2023 to 2024. The gross margin has remained relatively stable, with a slight increase from 155.66% in 2023 to 155.97% in 2024, indicating effective cost management in relation to revenue generation. The revenue breakdown by product shows a significant increase in specialised health services from 58,514 in 2022 to 70,601 in 2024, while general health services have decreased from 4,440 in 2022 to 3,596 in 2024. Geographically, revenue from Malaysia has increased from 49,696 in 2022 to 59,597 in 2024, while Singapore's revenue has slightly decreased from 12,047 in 2023 to 11,852 in 2024, and Myanmar has shown growth from 1,916 in 2022 to 2,748 in 2024. |
| Operating Efficiency | Operating margin data is not available for the years analyzed, but the net profit margin has shown a declining trend from 20.17% in 2022 to 18.79% in 2023, and further down to 17.38% in 2024. This indicates a deterioration in profitability relative to revenue over the analyzed period. The operating expenses have increased from 13,942 in 2023 to 15,908 in 2024, which may suggest challenges in cost management despite revenue growth. The relationship between operating income and revenue cannot be assessed due to the lack of operating income data. |
| External & One-Off Impact | The effective tax rate has seen a slight increase from 24.14% in 2022 to 24.05% in 2023, and then to 24.98% in 2024, indicating a potential increase in tax burden on profits. The net profit has fluctuated, with a slight decrease from 13,150 in 2023 to 12,894 in 2024, despite revenue growth, which may suggest the impact of rising operating expenses and tax rates. There are no specific non-recurring items mentioned, but the overall external economic environment may be influencing profitability through increased costs and tax obligations. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | In 2024, the company demonstrated a strong financial position with total assets increasing to 119,046, up from 107,107 in 2023. This growth was primarily driven by a significant rise in non-current assets, which reached 94,191, compared to 80,086 in 2023. Total liabilities also increased to 27,307, but the debt to equity ratio improved slightly to 29.77%, indicating better equity management. The current ratio decreased to 148.25%, reflecting a tighter liquidity position compared to 186.75% in 2023, suggesting a need for improved short-term asset management. | In 2023, the company maintained a solid financial foundation with total assets of 107,107, a slight decrease from 110,295 in 2022. The total liabilities were 24,957, which was lower than the previous year, resulting in a debt to equity ratio of 30.38%. The current ratio was strong at 186.75%, indicating good short-term liquidity. However, the decline in total assets and the increase in liabilities suggest a need for careful monitoring of financial health moving forward. |
| Profitability and earnings quality | The company reported revenue of 74,197 in 2024, a notable increase from 69,994 in 2023, reflecting a growth trend in revenue generation. Gross profit also rose to 32,668, with a gross margin of 155.97%, slightly up from 155.66% in 2023. However, the net profit margin decreased to 17.38% from 18.79%, indicating potential pressures on profitability. Return on equity (ROE) was 14.83%, down from 16.09% in 2023, suggesting a decline in earnings quality despite higher revenues. | In 2023, the company achieved a revenue of 69,994, up from 62,954 in 2022, indicating a positive growth trajectory. The gross profit was 31,036, with a gross margin of 155.66%. The net profit margin was 18.79%, which was higher than the previous year's 20.17%, indicating a slight decline in profitability. The return on equity was 16.09%, reflecting strong earnings quality, although the trend suggested a need for improved cost management to sustain profitability. |
| Operational efficiency | In 2024, the operating expenses increased to 15,908, which may indicate rising costs that could impact operational efficiency. The asset turnover ratio improved to 65.62%, up from 64.39% in 2023, suggesting better utilization of assets to generate revenue. Net cash from operations was 17,642, slightly higher than 17,171 in 2023, indicating stable cash flow management despite increased operational costs. | The operational efficiency in 2023 was characterized by operating expenses of 13,942, which were manageable given the revenue growth. The asset turnover ratio was 64.39%, indicating effective use of assets. Net cash from operations was 17,171, showing strong cash flow generation capabilities, although the company should focus on controlling costs to enhance overall efficiency. |
| Financial risk identification and early warning | In 2024, the company faced increased financial risk with a current ratio of 148.25%, down from 186.75% in 2023, indicating potential liquidity concerns. The debt to equity ratio improved slightly to 29.77%, suggesting effective debt management. However, the effective tax rate increased to 24.98%, which could impact net profitability. Monitoring these indicators will be crucial to mitigate financial risks. | In 2023, the company had a strong current ratio of 186.75%, indicating good liquidity. The debt to equity ratio was 30.38%, reflecting a balanced approach to leverage. The effective tax rate was 24.05%, which was stable compared to previous years. Overall, the financial risk profile appeared manageable, but vigilance is necessary as liabilities increased. |
| Future financial performance projection | Looking ahead, the company is positioned for growth with a revenue increase to 74,197 in 2024. Investment activities have ramped up, as indicated by net cash from investing of (12,780), suggesting a focus on expansion. However, the net cash from financing decreased to (9,129), indicating potential challenges in funding operations. The company should focus on maintaining cash flow sustainability and consider strategic investments to support future growth. | In 2023, the company showed promising signs of future performance with revenue growth to 69,994. The net cash from investing was (6,432), indicating ongoing investment in growth initiatives. However, net cash from financing was (11,305), which may pose challenges for future funding. The company should prioritize cash flow management and explore opportunities for market expansion to ensure continued growth. |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | ISEC Healthcare Ltd. operates primarily through the provision of specialized health services, particularly in the field of ophthalmology, and general health services. The company generates revenue through consultation, medication, and procedures, with a significant portion coming from specialized health services, which accounted for S$70.6 million in revenue for FY2024. The company also earns revenue from general health services, which contributed S$3.6 million. Revenue is recognized at a point in time when services are rendered. | ISEC Healthcare Ltd. operates primarily through the provision of specialized health services, particularly in the field of ophthalmology, and general health services. The company generates revenue through consultation, medication, and procedures, with a significant portion coming from specialized health services, which accounted for S$66.0 million in FY2023. The revenue is recognized at a point in time when services are rendered. The company also engages in general healthcare services, which include medical care and procedural treatment services. |
| Market Position | ISEC Healthcare is positioned as a market leader in the ophthalmology sector within its operational regions, particularly in Malaysia and Singapore. In FY2024, the company reported a total revenue of S$74.2 million, with Malaysia contributing S$59.6 million, indicating a 6% growth from the previous year. The company operates multiple specialized centers and has expanded its footprint in Malaysia, increasing its market share. In Singapore, the company operates one specialist center and four GP clinics, generating S$11.9 million in revenue. The company is recognized for its high-quality eye care services and is actively exploring regional expansion opportunities. | ISEC Healthcare is a market leader in the ophthalmology sector within its key markets of Malaysia and Singapore, with Malaysia accounting for 80% of total revenue in FY2023. The company reported a total revenue of S$70.0 million in FY2023, an 11% increase from the previous year, indicating strong growth. The company has expanded its footprint in emerging markets like Myanmar and is exploring opportunities in Cambodia and Vietnam, highlighting its competitive position and growth strategy. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | The Group faces market risks including demand volatility and competition, particularly in the healthcare sector. The rising costs and competition in Singapore have adversely affected the performance of certain subsidiaries, leading to a decrease in revenue for general health services. | The Group faces market risks including demand volatility and competition in the healthcare sector, particularly in emerging markets like Myanmar, Cambodia, and Vietnam. The company is exploring expansion opportunities to mitigate these risks. |
| Operational Risks | Operational risks include challenges related to the expansion of services and the opening of new centers, which may lead to increased operational costs. Additionally, the Group's reliance on technology systems and human resources for service delivery poses risks to business continuity and quality of care. | Operational risks include challenges in maintaining a skilled workforce in a competitive labor market and ensuring the quality of medical services. The Group conducts regular training for staff and engages in fire drills to enhance operational readiness. |
| Financial Risks | The Group is exposed to credit risk, foreign currency risk, liquidity risk, and interest rate risk. To mitigate these risks, the Group actively manages cash flows and maintains sufficient credit facilities. The sensitivity analysis indicates that a 50 basis point change in interest rates could significantly impact profits. | The Group is exposed to credit risks, foreign currency risks, liquidity risks, and interest rate risks. To manage these, the Group employs strategies such as risk identification, exposure limits, and maintaining sufficient cash levels to meet obligations. |
| Compliance Risks | The Group is subject to various regulatory compliance requirements, including adherence to the Companies Act and accounting standards. The Board is committed to maintaining high corporate governance standards and regularly reviews compliance with applicable laws and regulations. | The Group is subject to various regulatory requirements and has established internal controls to ensure compliance with legal and statutory obligations. The Audit Committee oversees compliance and internal controls to mitigate risks associated with non-compliance. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| Dr Lee Hung Ming | Executive Vice Chairman | £883,000 |
| Dr Wong Jun Shyan | Chief Executive Officer | £1,431,000 |
| Mr Chong Weng Hoe | Non-Executive Chairman and Independent Director | £70,000 |
| Ms Wee Kim Lin Evelyn | Non-Executive and Independent Director | £34,000 |
| Mr Chen Bang | Non-Executive and Non-Independent Director | N/A |
| Mr Li Li | Non-Executive and Non-Independent Director | N/A |
| Ms Zhang Yongmei | Non-Executive and Non-Independent Director | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | The Group's internal controls and systems are designed to provide reasonable assurance as to the integrity and reliability of the financial information, and to safeguard and maintain accountability of assets. Procedures are in place to identify major business risks and evaluate potential financial implications. The Management regularly reviews the Group's business and operations to identify areas of significant business risks and controls to mitigate the risks. The Board has approved a 'Risk Governance and Internal Control Framework Manual' which includes policies such as Code of Ethics, Risk Appetite and Risk Tolerance Guidance, Authority and Risk Control Matrix, Key Control Activities, and Key Reporting and Monitoring Activities. | The Group's internal controls and systems are designed to provide reasonable assurance as to the integrity and reliability of financial information, and to safeguard and maintain accountability of assets. Procedures are in place to identify major business risks and evaluate potential financial implications. The Management regularly reviews the Group's business and operations to identify areas of significant business risks and controls to mitigate the risks. |
| Control activities | The AC reviews the adequacy and effectiveness of the Group's system of internal controls, including financial, operational, compliance, and information technology controls, and risk management policies and systems established by Management on an annual basis. The design, implementation, and operation of the accounting and internal control systems are intended to prevent and detect fraud and errors. The Company has a whistle-blowing policy whereby staff and external parties can raise concerns about possible irregularities in financial reporting or other matters. | The Group has adopted a 'Risk Governance and Internal Control Framework Manual' which includes a Code of Ethics, Risk Appetite and Risk Tolerance Guidance, Authority and Risk Control Matrix, Key Control Activities, and Key Reporting and Monitoring Activities. The internal audit function is outsourced to NLA Risk Consulting Pte. Ltd., which reports directly to the Audit Committee (AC). The AC reviews the adequacy and effectiveness of the Group's internal controls, including financial, operational, compliance, and information technology controls. |
| Monitoring mechanisms | The AC meets with the external auditor and internal auditors at least annually without the presence of Management. The internal audit function is outsourced to NLA Risk Consulting Pte. Ltd., which reports directly to the AC. The AC reviews the internal audit program, scope, and reports on a periodic basis and monitors Management's responsiveness to findings and recommendations by the internal auditor. | The Audit Committee oversees the internal audit function and receives reports from NLA on internal procedures and internal control weaknesses. The AC reviews the internal audit program, scope, and reports on a periodic basis and monitors Management's responsiveness to findings and recommendations. The AC also reviews whistle-blowing complaints and has the authority to conduct investigations. |
| Identified material weaknesses or deficiencies | Impairment loss of $1,520,000 was recognized during the financial year, indicating a material weakness in the assessment of goodwill. | During FY2023, the internal auditors identified and recommended areas for improvement on certain internal processes but did not come across any other matters that required further review. |
| Effectiveness | The Board, with the concurrence of the AC, is of the opinion that the Group's internal controls (including financial, operational, compliance, and information technology controls) and risk management systems are adequate and effective for FY2024. | The AC is satisfied that the internal audit function is independent, effective, and adequately resourced. The Board, with the concurrence of the AC, is of the opinion that the Group's internal controls and risk management systems are adequate and effective for FY2023. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | The Group remains keen on regional expansion and continues to explore opportunities to expand its footprint across existing markets and enter new ones, particularly in Vietnam where discussions are ongoing. Additionally, the Group completed the conditions of a Sale and Purchase Agreement to acquire certain strata-titled units in Kuala Lumpur for a new purpose-built medical centre, expected to be operational by 2027. | The Group is exploring opportunities to expand its footprint across existing markets and enter new ones, potentially through fund-raising to support these expansion plans. In December 2023, the Group signed a sales and purchase agreement for the acquisition of strata-titled units totaling 69,445 sqft in a purpose-built medical center in Kuala Lumpur, which is expected to enhance service capacity and reduce lease expenses. |
| New technologies | The Group is committed to continuously upgrading its skills and enhancing its equipment with the latest technology to remain future-ready. Specific technologies or platforms were not detailed in the report. | The report highlights ongoing commitments to enhance the skills of medical staff through training programs, including the ISEC Intermediate Cataract Surgery course. Additionally, the Group's medical specialists participate in seminars to share insights on advancements in surgical techniques and technologies, such as Optical Coherence Tomography Angiography (OCTA). |
| Organisational Restructuring | In December 2024, the Group organized a teambuilding event for its KL staff to promote friendship, team bonding, and effective communication. Various training courses were provided to staff, covering topics such as dry eye treatment and myopia control management. | The Group is actively looking to enlarge its talent pool and medical team to support expanding operations. In a competitive labor market, the Group reviews staff remuneration and benefits to attract and retain talent. The ISEC Healthcare Performance Share Plan is also mentioned as a means to engage employees in the company's growth. |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | The Group faces economic challenges primarily due to rising operating costs influenced by inflation, particularly in Myanmar, which has led to increased fees to reflect these higher costs. Additionally, the overall increase in operational costs has impacted profitability, as seen in the recognition of an impairment loss for goodwill related to the Group's GP clinics in Singapore. The economic environment remains uncertain, affecting revenue growth and operational expenses. | The Group faces economic challenges including interest rate risks due to borrowings at floating rates, which may fluctuate with market interest rates. Additionally, there are liquidity risks that could affect the Group's ability to meet short-term obligations, necessitating careful management of cash flows and credit facilities. The Group's exposure to credit risks and foreign currency risks also adds to the economic uncertainties that could impact financial performance. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | The Group is experiencing competitive pressures in the healthcare sector, particularly in Singapore, where rising costs and competition have adversely affected the performance of its general health services segment. The revenue from these services has declined significantly, indicating a challenging market environment. Furthermore, the Group has recognized impairment losses for goodwill in subsidiaries due to these competitive dynamics, highlighting the impact of market competition on its financial performance. | The Group operates in a highly competitive healthcare market, facing pressures from both established players and new entrants. The need to attract and retain talent in a competitive labor market is critical for supporting expansion plans. Furthermore, the Group is aware of potential competitive threats from similar businesses, particularly from Aier Eye Hospital Group, which operates in the same sector. |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | In 2024, ISEC Healthcare Ltd. made significant R&D investments, totaling $234,000 in software under development. This investment is aimed at enhancing technology and improving product offerings to meet market demands. The company is focused on advancing its digital capabilities and integrating new technologies into its healthcare services, reflecting a commitment to innovation in the medical eye care sector. | In 2023, ISEC Healthcare Ltd. made significant R&D investments, particularly in the development of computer software, with an addition of $89,000 to software under development. The company focuses on enhancing its technological capabilities and improving its product offerings to meet market demands. The total carrying amount for software under development as of December 31, 2023, is $219,000, indicating a commitment to advancing technology in the healthcare sector. |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | In 2024, ISEC Healthcare Ltd. launched several new centers in Malaysia, including ME Centre Sdn. Bhd., Taiping Eye Sdn. Bhd., and TE Centre Sdn. Bhd., which commenced operations in September 2024. These centers are designed to provide ambulatory care services, showcasing the company's strategy to expand its footprint and enhance service delivery in response to increasing demand for eye care services. | In March 2023, ISEC Healthcare Ltd. launched its new eye specialist clinic, ISEC (Kuching) Sdn. Bhd., in Malaysia, which received its operating license from the Ministry of Health. This new clinic aims to provide specialized medical eye care services, reflecting the company's strategy to expand its footprint in the region and cater to the growing demand for ophthalmology services. The clinic's opening is part of ISEC's broader commitment to introducing differentiated healthcare services in emerging markets. |
